Abstract:Chimeric antigen receptor (CAR) T cell therapy, while highly efficacious for the treatment of certain haematological malignancies, remains ineffective in solid cancers. This can be attributed to various factors, including immunosuppression and heterogeneous expression of targetable tumor antigens. Our previous work (Lai et al. 2020, Nature Immunology) demonstrated that engineering CAR T cells to engage host immunity is key to effectively treating heterogenous tumors. "Armouring" CAR T cells to express proinflammatory cytokines is a promising strategy to engage endogenous anti-tumor immunity. However, conventional armouring approaches that utilize a synthetic promoter to drive cytokine expression (e.g. NFAT promoter) lead to systemic expression of transgenes, which can cause severe clinical toxicities when potent cytokines such as IL-12 are employed. In the current work, we engineered CAR T cells to express anti-tumor factors under the transcriptional control of tumor-specific promoters, and hypothesised that this would enhance the safety and efficacy of armoured CAR T cells (Chen et al. in revision, Cell). Genome-wide RNA-sequencing was used to identify genes in CAR T cells with tumor-specific expression. A novel CRISPR/Cas9-mediated homology directed repair strategy was then employed to knock in (KI) anti-cancer factors into these gene loci. NR4A2 was identified as the promoter with the highest degree of tumor-site restriction and T cells were subsequently engineered to express cytokines from this promoter. This approach was applied to syngeneic CAR T and OT-I murine models that enable clinically relevant assessment of efficacy and safety. CRISPR-engineered primary murine and human CAR T cells exhibited gene KI efficiency of ∼50%. Integrating proinflammatory cytokines such as IL-12 into the NR4A2 promoter led to antigen-specific induction of transgene expression in tumor cocultures, and tumor-restricted expression in vivo. Importantly, this strategy achieved significantly improved tumor-site specific expression of transgenes relative to the NFAT promoter system. Tumor-specific induction of IL-12 improved anti-tumor efficacy leading to eradication of established tumors and activation of host immunity/epitope spreading that enabled effective treatment of heterogenous tumors. Importantly, this approach did not lead to significant systemic expression of IL-12, and provided a favourable safety profile. We were able to demonstrate that this approach was equally scalable as conventional CAR T cell generation protocols and could be applied to either autologous patient-derived CAR T cells or through a CRISPR Knock-In approach to generate CAR T from allogenic health donor-derived PBMCs. We therefore posit that this technology has the potential to enable the armoring of CAR T cells with cargos that are highly potent and require exquisite tumor-site specific expression of transgenes. Citation Format: Paul Beavis. CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-02.

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

Abstract PR-02: CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells

Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation

CRISPR/Cas-based CAR-T cells: production and application

Genome-wide CRISPRa screens nominate modulators of CAR T cell survival within distinct tumor cytokine milieus

Universal CARs, universal T cells, and universal CAR T cells

Engineering strategies to safely drive CAR T-cells into the future

CAR T cells: Building on the CD19 paradigm

CRISPR/Cas-mediated non-viral genome specific targeted CAR T cells achieve high safety and efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

Physiological (TCR-like) regulated lentiviral vectors for the generation of improved CAR-T cells